Nitin Jain, MD, is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, TX.
Dr Jain received a medical degree in 2002 from the All India Institute of Medical Sciences (AIIMS), New Delhi, India. He then moved to the United States in 2004 where he completed his clinical residency at the Medical College of Wisconsin, Milwaukee, WI. From 2007 till 2012, Dr Jain completed several fellowships at the MD Anderson Cancer Center in Texas, the Memorial Sloan-Kettering Cancer Center in New York and the University of Chicago. In 2012, Dr Jain accepted a role as a faculty member in the Department of Leukemia at the MD Anderson Cancer Center, where he still works today.
Speaking on new drug developments in CLL and ALL
Dr Jain is involved in several clinical Phase I and II trials as a Principal Investigator. These trials focus on targeted therapies, combination chemotherapies and checkpoint inhibitors in chronic lymphocytic leukemia (CLL), and Richter transformation, JAK2 inhibitors, novel CD22 antibodies, and allogeneic CAR-T in acute lymphoblastic leukemia (ALL).